Dr Reddy’s Laboratories, after market hours on Tuesday, informed the exchanges that it has launched Sirolimus tablet variants (1 mg and 2 mg) in the US. Sirolimus is used to prevent rejection in organ transplants; it is especially useful in kidney transplants. According to the company, its equivalent Rapamune brand for the year ended August recorded sales of $206 million in the US markets. On October 27, the company received US FDA nod for marketing the product.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.